Pembrolizumab is a highly selective humanized monoclonal antibody that blocks the interaction between programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, which helps restore T-cell responses against tumor cells [1–4]. Here, CD274 is linked to neoplasm.